AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: Results of an IAEA multicentre randomised trial


Dobrowsky W., Huigol N. G., Jayatilake R. S., Kizilbash N., Okkan S., Kagiya V. T., ...Daha Fazla

RADIOTHERAPY AND ONCOLOGY, cilt.82, sa.1, ss.24-29, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 82 Sayı: 1
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/j.radonc.2006.11.007
  • Dergi Adı: RADIOTHERAPY AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.24-29
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Purpose: AK-2123, a nitrotriazole hypoxic cell sensitizer, has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage III and IV.